3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
4
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
pembrolizumab
8
cemiplimab
5
Nivolumab
4
Ipilimumab
4
Blood Specimen Collection
3
lifileucel
2
avelumab
2
aldesleukin
2
Niacinamide
2
Cyclophosphamide
2
toripalimab
1
tislelizumab
1
oxycodone-acetaminophen
1
lenvatinib
1
fludarabine
1
epacadostat
1
encorafenib
1
durvalumab
1
dostarlimab
1
brodalumab
1
binimetinib
1
atezolizumab
1
Vitamin A
1
Surgical Procedures, Operative
1
Sunscreening Agents
1
Standard of Care
1
Specimen Handling
1
Resistance Training
1
Radiotherapy
1
Niacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
90 days
×
Clear all
No trials found.